DeLLphi-301 - FDA Approval of Tarlatamab in Patients w/ Prev Treated Small Cell Lung Cancer (SCLC)

In this episode of the Oncology Brothers podcast, hosts Drs. Rahul and Rohit Gosain dive into the recent FDA approval of tarlatamab, a groundbreaking bispecific antibody for patients with extensive stage small cell lung cancer. Joined by Dr. Misty Shields from Indiana University, they explore the DeLLphi-301 study design, the efficacy of tarlatamab, and the operational challenges associated with its use.

Key topics discussed include:
•⁠  ⁠The study's primary endpoint of objective response rate and its implications for patient care.
•⁠  ⁠The unique mechanism of action of tarlatamab targeting DLL3 and CD3 T cells.
•⁠  ⁠The importance of monitoring for side effects such as cytokine release syndrome (CRS) and immune cell-associated neurotoxicity syndrome (ICANS).
•⁠  ⁠Strategies for community oncologists to effectively manage patients receiving this new treatment.

Dr. Shields also highlights the significance of patient advocacy and the role of organizations like Longevity Small Cell Smashers in supporting those affected by small cell lung cancer.

Tune in for an insightful discussion that sheds light on the future of treatment options for small cell lung cancer and the collaborative efforts needed to ensure patient safety and care.

Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!

Website: http://www.oncbrothers.com/

X/Twitter: https://twitter.com/oncbrothers

Contact us at info@oncbrothers.com